View Item 

Show simple item record

Vitamin D and Cardiovascular Disease

dc.contributor.authorNemerovski, Carrie W.en_US
dc.contributor.authorDorsch, Michael Pen_US
dc.contributor.authorSimpson, Robert U.en_US
dc.contributor.authorBone, Henry G.en_US
dc.contributor.authorAaronson, Keith D.en_US
dc.contributor.authorBleske, Barry E.en_US
dc.date.accessioned2012-03-16T15:57:53Z
dc.date.available2012-03-16T15:57:53Z
dc.date.issued2009-06en_US
dc.identifier.citationNemerovski, Carrie W.; Dorsch, Michael P; Simpson, Robert U.; Bone, Henry G.; Aaronson, Keith D.; Bleske, Barry E. (2009). "Vitamin D and Cardiovascular Disease." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29(6). <http://hdl.handle.net/2027.42/90252>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90252
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherVascular Diseaseen_US
dc.subject.other1,25‐Dihydroxyvitamin Den_US
dc.subject.other1,25(OH) 2 Den_US
dc.subject.other25‐Hydroxyvitamin Den_US
dc.subject.other25(OH)Den_US
dc.subject.otherCardiologyen_US
dc.subject.otherCardiovascular Diseaseen_US
dc.subject.otherHeart Failureen_US
dc.subject.otherHypertensionen_US
dc.subject.otherVitamin Den_US
dc.titleVitamin D and Cardiovascular Diseaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartments of Pharmacy Services, University of Michigan Health System, Ann Arbor, Michiganen_US
dc.contributor.affiliationumInternal Medicine, Division of Cardiology, University of Michigan Health System, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartments of Pharmacology, University of Michigan Medical School, Ann Arbor, Michiganen_US
dc.contributor.affiliationumInternal Medicine, Divisions of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, Michiganen_US
dc.contributor.affiliationumCardiology, University of Michigan Medical School, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherMichigan Bone and Mineral Clinic, P.C., Detroit, Michigan.en_US
dc.identifier.pmid19476421en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90252/1/phco.29.6.691.pdf
dc.identifier.doi10.1592/phco.29.6.691en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceGiovannucci, E., Liu, Y., Hollis, B.W., Rimm, E.B.. 25‐Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168: 1174 – 80.en_US
dc.identifier.citedreferenceKristal‐Boneh, E., Froom, P., Harari, G., Ribak, J.. Association of calcitriol and blood pressure in normotensive men. Hypertension 1997; 30: 1289 – 94.en_US
dc.identifier.citedreferenceScragg, R., Holdaway, I., Singh, V., Metcalf, P., Baker, J., Dryson, E.. Serum 25‐hydroxycholecalciferol concentration in newly detected hypertension. Am J Hypertens 1995; 8: 429 – 32.en_US
dc.identifier.citedreferenceScragg, R., Sowers, M.F., Bell, C.. Serum 25‐hydroxyvitamin D, ethnicity, and blood pressure in the third national health and nutrition examination survey. Am J Hypertens 2007; 20: 713 – 19.en_US
dc.identifier.citedreferenceSnijder, M.B., Lips, P., Seidell, J.C., et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population‐based study in older men and women. J Intern Med 2007; 261: 558 – 65.en_US
dc.identifier.citedreferenceForman, J.P., Giovannucci, E., Holmes, M.D., et al. Plasma 25‐hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49: 1063 – 9.en_US
dc.identifier.citedreferenceSugden, J.A., Davies, J.I., Witham, M.D., Morris, A.D., Struthers, A.D.. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008; 25: 320 – 5.en_US
dc.identifier.citedreferencePfeifer, M., Begerow, B., Minne, H.W., Nachtigall, D., Hansen, C.. Effects of a short‐term vitamin D 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86: 1633 – 7.en_US
dc.identifier.citedreferenceMelamed, M.L., Muntner, P., Michos, E.D., et al. Serum 25‐hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 2008; 28: 1179 – 85.en_US
dc.identifier.citedreferenceTargher, G., Bertolini, L., Padovani, R., et al. Serum 25‐hydroxyvitamin D3 concentrations and carotid artery intima‐media thickness among type 2 diabetic patients. Clin Endocrinol 2006; 65: 593 – 7.en_US
dc.identifier.citedreferenceLindén, V.. Vitamin D and myocardial infarction. Br Med J 1974; 3: 647 – 50.en_US
dc.identifier.citedreferenceLund, B., Badskjaer, J., Lund, B.J., Soerensen, O.H.. Vitamin D and ischaemic heart disease. Horm Metab Res 1978; 10: 553 – 6.en_US
dc.identifier.citedreferenceSchmidt‐Gayk, H., Goossen, J., Lendle, F., Seidel, D.. Serum 25‐hydroxycalciferol in myocardial infarction. Atherosclerosis 1977; 26: 55 – 8.en_US
dc.identifier.citedreferenceVik, B., Try, K., Thelle, D.S., Forde, O.H.. Tromsø heart study: vitamin D metabolism and myocardial infarction [short report]. Br Med J 1979; 2: 176.en_US
dc.identifier.citedreferenceCigolini, M., Iagulli, M.P., Miconi, V., et al. Serum 25‐hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006; 29: 722 – 4.en_US
dc.identifier.citedreferenceWang, T.J., Pencina, M.J., Booth, S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503 – 11.en_US
dc.identifier.citedreferenceDobnig, H., Pilz, S., Scharnagl, H., et al. Independent association of low serum 25‐hydroxyvitamin D and 1,25‐dihydroxyvitamin D levels with all‐cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340 – 9.en_US
dc.identifier.citedreferenceAutier, P., Gandini, S.. Vitamin D supplementation and total mortality: a meta‐analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730 – 7.en_US
dc.identifier.citedreferenceMelamed, M.L., Michos, E.D., Post, W., Astor, B.. 25‐Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629 – 37.en_US
dc.identifier.citedreferenceHsia, J., Heiss, G., Ren, H., et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846 – 54.en_US
dc.identifier.citedreferenceNational Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington DC: National Osteoporosis Foundation; 2008.en_US
dc.identifier.citedreferenceBoxer, R.S., Dauser, D.A., Walsh, S.J., Hager, W.D., Kenny, A.M.. The association between vitamin D and inflammation with the 6‐minute walk and frailty in patients with heart failure. J Am Geriatr Soc 2008; 56: 454 – 61.en_US
dc.identifier.citedreferenceArroyo, M., Laguardia, S.P., Bhattacharya, S.K., et al. Micronutrients in African‐Americans with decompensated and compensated heart failure. Transl Res 2006; 148: 301 – 8.en_US
dc.identifier.citedreferenceLaguardia, S.P., Dockery, B.K., Bhattacharya, S.K., Nelson, M.D., Carbone, L.D., Weber, K.T.. Secondary hyperparathyroidism and hypovitaminosis D in African‐Americans with decompensated heart failure. Am J Med Sci 2006; 332: 112 – 18.en_US
dc.identifier.citedreferenceShane, E., Mancini, D., Aaronson, K., et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997; 103: 197 – 207.en_US
dc.identifier.citedreferenceZittermann, A., Schleithoff, S.S., Tenderich, G., Berthold, H.K., Koerfer, R., Stehle, P.. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105 – 12.en_US
dc.identifier.citedreferenceZittermann, A., Schleithoff, S.S., Gotting, C., et al. Poor outcome in end‐stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 2008; 10: 321 – 7.en_US
dc.identifier.citedreferencePilz, S., Marz, W., Wellnitz, B., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross‐sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008; 93: 3927 – 35.en_US
dc.identifier.citedreferenceSchleithoff, S.S., Zittermann, A., Tenderich, G., Berthold, H.K., Stehle, P., Koerfer, R.. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double‐blind, randomized, placebo‐controlled trial. Am J Clin Nutr 2006; 83: 754 – 9.en_US
dc.identifier.citedreferenceLonn, E., Yusuf, S., Arnold, M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567 – 77.en_US
dc.identifier.citedreferenceManson, J.E., Hsia, J., Johnson, K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523 – 34.en_US
dc.identifier.citedreferenceRossouw, J.E., Prentice, R.L., Manson, J.E.. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465 – 77.en_US
dc.identifier.citedreferenceWaters, D.D., Alderman, E.L., Hsia, J., et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288: 2432 – 40.en_US
dc.identifier.citedreferenceHeart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002; 360: 23 – 33.en_US
dc.identifier.citedreferenceHathcock, J.N., Shao, A., Vieth, R., Heaney, R.. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85: 6 – 18.en_US
dc.identifier.citedreferenceWootton, A.M.. Improving the measurement of 25‐hydroxyvitamin D. Clin Biochem Rev 2005; 26: 33 – 6.en_US
dc.identifier.citedreferenceShoback, D., Sellmeyer, D., Bikle, D.. Greenspan's basic and clinical endocrinology, 8th ed. Columbus, OH: The McGraw‐Hill Companies, 2007.en_US
dc.identifier.citedreferenceHolick, M.F.. Vitamin D deficiency. N Engl J Med 2007; 357: 266 – 81.en_US
dc.identifier.citedreferenceWikvall, K.. Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form (review). Int J Mol Med 2001; 7: 201 – 9.en_US
dc.identifier.citedreferenceLi, Y.C., Qiao, G., Uskokovic, M., Xiang, W., Zheng, W., Kong, J.. Vitamin D: a negative endocrine regulator of the renin‐angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89–90: 387 – 92.en_US
dc.identifier.citedreferenceZhou, C., Assem, M., Tay, J.C., et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug‐induced osteomalacia. J Clin Invest 2006; 116: 1703 – 12.en_US
dc.identifier.citedreferenceHolick, M.F., Chen, T.C.. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008; 87: S1080 – 6.en_US
dc.identifier.citedreferenceHolick, M.F.. Vitamin D status: measurement, interpretation, and clinical application [published online ahead of print March 8, 2008]. Ann Epidemiol 2008. Available from http:dx.doi.org10.1016j.annepidem.2007.12.001.en_US
dc.identifier.citedreferenceHeaney, R.P.. Vitamin D endocrine physiology. J Bone Miner Res 2007; 22: V25 – 7.en_US
dc.identifier.citedreferenceHeaney, R.. Vitamin D and calcium interactions: functional outcomes. Am J Clin Nutr 2008; 88 ( suppl ): S541 – 4.en_US
dc.identifier.citedreferenceJanssen, H.C.. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002; 75: 611 – 15.en_US
dc.identifier.citedreferenceWebb, A.R., Kline, L., Holick, M.F.. Influence of season and latitude on the cutaneous synthesis of vitamin D 3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D 3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373 – 8.en_US
dc.identifier.citedreferenceWeishaar, R.E., Kim, S.N., Saunders, D.E., Simpson, R.U.. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990; 258: E134 – 42.en_US
dc.identifier.citedreferenceWeishaar, R.E., Simpson, R.U.. Vitamin D3 and cardiovascular function in rats. J Clin Invest 1987; 79: 1706 – 12.en_US
dc.identifier.citedreferenceWeishaar, R.E., Simpson, R.U.. Involvement of vitamin D3 with cardiovascular function II. Direct and indirect effects. Am J Physiol Endocrinol Metab 1987; 253: E675 – 83.en_US
dc.identifier.citedreferenceZittermann, A., Schleithoff, S.S., Koerfer, R.. Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Fail Rev 2006; 11: 25 – 33.en_US
dc.identifier.citedreferenceRostand, S.G., Drueke, T.B.. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383 – 92.en_US
dc.identifier.citedreferencePark, C.W., Oh, Y.S., Shin, Y.S., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73 – 81.en_US
dc.identifier.citedreferenceShoji, T., Shinohara, K., Kimoto, E., et al. Lower risk for cardiovascular mortality in oral 1‐alpha‐hydroxy vitamin D 3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179 – 84.en_US
dc.identifier.citedreferenceTeng, M., Wolf, M., Ofsthun, M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115 – 25.en_US
dc.identifier.citedreferenceDrüeke, T., Fleury, J., Toure, Y., et al. Effect of parathyroidectomy on left‐ventricular function in haemodialysis patients. Lancet 1980; 1: 112 – 14.en_US
dc.identifier.citedreferenceGafter, U., Battler, A., Eldar, M., et al. Effect of hyperparathyroidism on cardiac function in patients with end‐stage renal disease. Nephron 1985; 41: 30 – 3.en_US
dc.identifier.citedreferenceDeLuca, H.F.. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80: S1689 – 96.en_US
dc.identifier.citedreferenceNibbelink, K.A., Tishkoff, D.X., Hershey, S.D., Rahman, A., Simpson, R.U.. 1,25(OH) 2 ‐vitamin D 3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL‐1 cardiac myocyte. J Steroid Biochem Mol Biol 2007; 103: 533 – 7.en_US
dc.identifier.citedreferenceWalters, M.R., Ilenchuk, T.T., Claycomb, W.C.. 1,25‐dihydroxyvitamin D3 stimulates 45Ca2 uptake by cultured adult rat ventricular cardiac muscle cells. J Biol Chem 1987; 262: 2536 – 41.en_US
dc.identifier.citedreferenceRahman, A., Hershey, S., Ahmed, S., Nibbelink, K., Simpson, R.U.. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol 2007; 103: 416 – 19.en_US
dc.identifier.citedreferenceSimpson, R.U., Hershey, S.H., Nibbelink, K.A.. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521 – 4.en_US
dc.identifier.citedreferenceXiang, W., Kong, J., Chen, S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin‐angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125 – 32.en_US
dc.identifier.citedreferenceLi, Y.C., Kong, J., Wei, M., et al. 1,25‐dihydroxyvitamin D3 is a negative endocrine regulator of the renin‐angiotensin system. J Clin Invest 2002; 110: 229 – 38.en_US
dc.identifier.citedreferenceZittermann, A., Koerfer, R.. Protective and toxic effects of vitamin D on vascular calcification: clinical implications. Mol Aspects Med 2008; 29: 423 – 32.en_US
dc.identifier.citedreferenceMann, D.L., Young, J.B.. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994; 105: 897 – 904.en_US
dc.identifier.citedreferenceCanning, M.O., Grotenhuis, K., Wit, H., Ruwhof, C., Drexhage, H.A.. 1‐alpha, 25‐dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001; 145: 351 – 7.en_US
dc.identifier.citedreferenceMüller, K., Haahr, P.M., Diamant, M., Rieneck, K., Kharazmi, A., Bendtzen, K.. 1,25‐Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the posttranscriptional level. Cytokine 1992; 4: 506 – 12.en_US
dc.identifier.citedreferenceZhu, Y., Mahon, B.D., Froicu, M., Cantorna, T.. Calcium and 1‐alpha, 25‐dihydroxyvitamin D3 target the TNF‐alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005; 35: 217 – 24.en_US
dc.identifier.citedreferenceDuprez, D., Buyzere, M., Backer, T., Clement, D.. Relationship between vitamin D3 and the peripheral circulation in moderate arterial primary hypertension. Blood Press 1994; 3: 389 – 93.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.29.6.691.pdf
Size:
294.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.